Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of Preeclampsia
American Journal of Perinatology · 01.05.2024 · 41 (S 01 S 01) · e2124-e2128
DOI: 10.1055/a-2099-8758 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2024. Verfasst von Arianna S Portmann-Baracco und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú. Hauptthemen laut MEDLINE: Pre-Eclampsia, COVID-19, SARS-CoV-2, Pregnancy Complications, Infectious. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objective
Our objective was to evaluate the association between severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) serologic status in immunologically naive patients and the risk of preeclampsia at the time of delivery. Study Design We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1 to September 30, 2020. We recorded maternal medical and obstetric characteristics and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed, and patients were classified into seropositive groups: immunoglobulin (Ig)G + , IgM + , or both IgG+ and IgM + . Bivariate and multivariable analyses were performed.
Results
We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p = 0.183) or with preeclampsia with severe features (p = 0.916) even after adjusting for maternal age >35, BMI ≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with the development of preeclampsia (odds ratio [OR] = 13.40; 95% confidence interval [CI]: 4.98–36.09; p < 0.05) and with preeclampsia with severe features (OR = 5.46; 95% CI: 1.65–18.02; p < 0.05).
Conclusion
We found that in an obstetric population, there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia. Key Points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Cayetano Heredia University, Lima, Perú.
- Department of Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, Texas.
ORCID-Profile: Arianna S Portmann-Baracco
Zitieren
APA
Portmann-Baracco, A. S., Alcorta-Proaño, R. G., Nuñez-Mochizaki, C., Webb, C. M., Trelles, J., Caparo, C., & La Rosa, M. F. (2024). Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of Preeclampsia. American Journal of Perinatology, 41(S 01 S 01), e2124-e2128. https://doi.org/10.1055/a-2099-8758
Vancouver
Portmann-Baracco AS, Alcorta-Proaño RG, Nuñez-Mochizaki C, Webb CM, Trelles J, Caparo C, et al. Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of Preeclampsia. American Journal of Perinatology. 2024;41(S 01 S 01):e2124-e2128. doi:10.1055/a-2099-8758
BibTeX
@article{PortmannBaracco2024,
author = {Portmann-Baracco, Arianna S and Alcorta-Proaño, Rodrigo G and Nuñez-Mochizaki, Claudia and Webb, Camille M and Trelles, Juan and Caparo, Carlos and La Rosa, Mauricio F},
title = {Severe Acute Respiratory Syndrome-Coronavirus-2 Antibody Status at the Time of Delivery and the Risk of Preeclampsia},
journal = {American Journal of Perinatology},
year = {2024},
volume = {41},
number = {S 01 S 01},
pages = {e2124--e2128},
doi = {10.1055/a-2099-8758}
}
EUVIMED